Cargando…
Baseline serum uric acid level is associated with progression-free survival, disease control rate, and safety in postoperative patients with colorectal cancer treated by FOLFOX, FOLFIRI, or XELOX
BACKGROUND: High serum uric acid (SUA) levels increase the risk of overall cancer morbidity and mortality, particularly for digestive malignancies. Nevertheless, the correlation between SUA level and clinical outcomes of the postoperative patients with colorectal cancer (CRC) treated by chemotherapy...
Autores principales: | Zhang, Xi, Chen, Qing-hong, Yang, Ying, Lin, Jing-xin, Li, Yan-chun, Zhong, Tian-yu, Chen, Jie, Wu, Si-qi, Chen, Xiao-hu, Zhou, Rui-si, Lin, Jia-man, Wang, Dong-qing, He, Qiu-xing, You, Yan-ting, Zhou, Xing-hong, Zuo, Qiang, Liu, Yan-yan, Cheng, Jing-ru, Wu, Yi-fen, Zhao, Xiao-shan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369254/ https://www.ncbi.nlm.nih.gov/pubmed/35965512 http://dx.doi.org/10.3389/fonc.2022.918088 |
Ejemplares similares
-
Efficacy of Postoperative FOLFOX Versus XELOX Chemotherapy for Gastric Cancer and Prognostic Value of Platelet–Lymphocyte Ratio in Patients Receiving XELOX
por: Yin, Xin, et al.
Publicado: (2020) -
Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement
por: Tse, Vicki C, et al.
Publicado: (2011) -
Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer
por: Jeon, Eun Kyoung, et al.
Publicado: (2011) -
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
por: Cassidy, J, et al.
Publicado: (2011) -
Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer
por: Ohta, Hideki, et al.
Publicado: (2017)